Olmesartan Medoxomilo + Hidroclorotiazida Ciclum (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Ciclum, is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to manage hypertension in adult patients, often in combination with a thiazide diuretic.

GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil combined with hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system to lower blood pressure. - Hypertension: helps achieve target blood pressure when monotherapy is insufficient. - Hypertensive urgency: provides gradual blood pressure reduction as part of a stepped‑care approach. - Edema associated with hypertension: reduces fluid retention through the diuretic component.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Liver enzyme elevation - Blood dyscrasias such as agranulocytosis

Before initiating therapy, consider patient‑specific factors and monitor relevant parameters. - Renal function: assess baseline creatinine and eGFR, adjust if impaired. - Electrolytes: monitor potassium and sodium levels regularly. - Pregnancy: avoid use; drug is contraindicated in the second and third trimesters. - Concomitant NSAIDs: increase risk of renal dysfunction and hyperkalemia. - Gout: may increase serum uric acid; monitor if patient has a history of gout. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil + hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - Aliskiren: combined use in diabetic patients can cause renal impairment and hyperkalemia. - Potassium‑saving diuretics or supplements: risk of dangerous hyperkalemia. - Lithium: increased lithium levels may lead to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs: additive hypotensive effect; monitor blood pressure. - Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.